Comparative Pharmacology
Head-to-head clinical analysis: NOGENIC HC versus ORTHO NOVUM 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOGENIC HC versus ORTHO NOVUM 1 35 21.
NOGENIC HC vs ORTHO-NOVUM 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NOGENIC HC contains hydrocortisone, a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription and reducing inflammation, immune responses, and cytokine production.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH and LH) secretion via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining, impairing sperm penetration and implantation.
NOGENIC HC is not a recognized drug. Please verify the name. No dosing information available.
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with hepatic impairment, half-life may be prolonged up to 24 hours; no dose adjustment required for renal impairment.
Norethindrone: 7-9 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal). At steady state, clinical contraceptive efficacy is maintained with daily dosing.
Primarily hepatic metabolism; biliary excretion accounts for approximately 80%; renal elimination of inactive metabolites less than 5% as unchanged drug.
Renal (approx. 40% as metabolites, <10% unchanged), fecal (approx. 60% as metabolites, primarily via bile).
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive